KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) FCF Margin: 2010-2025

Historic FCF Margin for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to -2.47%.

  • Emergent BioSolutions' FCF Margin fell 5281.00% to -2.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.18%, marking a year-over-year decrease of 1482.00%. This contributed to the annual value of 3.43% for FY2024, which is 2801.00% up from last year.
  • Latest data reveals that Emergent BioSolutions reported FCF Margin of -2.47% as of Q3 2025, which was down 103.36% from 73.46% recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' FCF Margin ranged from a high of 85.80% in Q2 2024 and a low of -121.18% during Q1 2023.
  • For the 3-year period, Emergent BioSolutions' FCF Margin averaged around 0.04%, with its median value being -2.47% (2025).
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by 9,838bps in 2023, then spiked by 12,336bps in 2024.
  • Emergent BioSolutions' FCF Margin (Quarterly) stood at 38.52% in 2021, then crashed by 1,041bps to 28.10% in 2022, then crashed by 2,062bps to 7.48% in 2023, then tumbled by 4,939bps to -41.91% in 2024, then crashed by 5,281bps to -2.47% in 2025.
  • Its FCF Margin was -2.47% in Q3 2025, compared to 73.46% in Q2 2025 and -6.66% in Q1 2025.